Premium
Consensus and controversies regarding the treatment of rhabdomyosarcoma
Author(s) -
Borinstein Scott C.,
Steppan Diana,
Hayashi Masanori,
Loeb David M.,
Isakoff Michael S.,
Binitie Odion,
Brohl Andrew S.,
Bridge Julia A.,
Stavas Mark,
Shinohara Eric T.,
Meyer William H.,
Reed Damon R.,
Wagner Lars M.
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26809
Subject(s) - medicine , rhabdomyosarcoma , multidisciplinary approach , clinical trial , intensive care medicine , sarcoma , clinical practice , medical physics , family medicine , pathology , social science , sociology
Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence‐based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.